Shares of Phibro Animal Health Co. (NASDAQ:PAHC - Get Free Report) have been given a consensus rating of "Strong Sell" by the five research firms that are currently covering the company, MarketBeat.com reports. Three investment analysts have rated the stock with a sell rating and two have assigned a hold rating to the company. The average 1 year price target among analysts that have covered the stock in the last year is $15.00.
PAHC has been the topic of several research reports. JPMorgan Chase & Co. assumed coverage on Phibro Animal Health in a research report on Tuesday, September 10th. They issued a "neutral" rating and a $22.00 target price on the stock. Bank of America raised their price objective on Phibro Animal Health from $13.00 to $15.00 and gave the stock an "underperform" rating in a report on Friday, August 30th.
Check Out Our Latest Research Report on PAHC
Phibro Animal Health Trading Up 0.9 %
Shares of NASDAQ PAHC traded up $0.20 on Wednesday, reaching $23.70. 159,761 shares of the company traded hands, compared to its average volume of 154,950. The stock has a market capitalization of $959.85 million, a PE ratio of 391.73, a P/E/G ratio of 0.58 and a beta of 0.52. Phibro Animal Health has a fifty-two week low of $9.40 and a fifty-two week high of $25.11. The company has a current ratio of 2.94, a quick ratio of 1.64 and a debt-to-equity ratio of 1.79. The company has a 50 day moving average of $21.94 and a 200 day moving average of $18.86.
Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last issued its quarterly earnings results on Wednesday, August 28th. The company reported $0.41 EPS for the quarter, topping the consensus estimate of $0.34 by $0.07. The firm had revenue of $273.16 million during the quarter, compared to analyst estimates of $262.44 million. Phibro Animal Health had a net margin of 0.24% and a return on equity of 18.08%. On average, equities research analysts forecast that Phibro Animal Health will post 1.57 earnings per share for the current fiscal year.
Insider Buying and Selling
In related news, Director E Thomas Corcoran acquired 5,000 shares of the business's stock in a transaction on Wednesday, September 4th. The shares were bought at an average cost of $20.02 per share, with a total value of $100,100.00. Following the completion of the transaction, the director now directly owns 25,000 shares of the company's stock, valued at $500,500. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 50.07% of the stock is owned by corporate insiders.
Institutional Trading of Phibro Animal Health
Several large investors have recently bought and sold shares of the company. CWM LLC increased its position in shares of Phibro Animal Health by 89.8% during the second quarter. CWM LLC now owns 2,188 shares of the company's stock worth $37,000 after acquiring an additional 1,035 shares during the last quarter. Fidelis Capital Partners LLC acquired a new stake in Phibro Animal Health in the first quarter valued at $46,000. nVerses Capital LLC acquired a new position in Phibro Animal Health during the 3rd quarter worth $70,000. Summit Securities Group LLC bought a new stake in shares of Phibro Animal Health in the 2nd quarter worth about $83,000. Finally, China Universal Asset Management Co. Ltd. raised its stake in shares of Phibro Animal Health by 63.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 3,912 shares of the company's stock valued at $88,000 after purchasing an additional 1,522 shares in the last quarter. Institutional investors and hedge funds own 99.34% of the company's stock.
About Phibro Animal Health
(
Get Free ReportPhibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.
See Also
Before you consider Phibro Animal Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Phibro Animal Health wasn't on the list.
While Phibro Animal Health currently has a "Strong Sell" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
